文献速递乳腺癌

转移性乳腺癌随机临床试验中局部研究者与盲法独立中心审查的无进展生存评估:系统综述与Meta分析

Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis.
PubMed 文献 · Eur J Cancer · 2023-12-12

该系统综述与Meta分析纳入24项随机临床试验、共13168例转移性乳腺癌患者,比较局部研究者与盲法独立中心审查评估的无进展生存期。总体合并差异指数为0.97(95%CI 0.85-1.10;ICC 0.831,p<0.001),提示两种评估方法间无统计学显著差异,支持局部研究者评估的无进展生存期作为主要终点的可靠性。

要点

  • 24项随机临床试验、13168例转移性乳腺癌患者中,局部研究者与盲法独立中心审查评估的无进展生存期无统计学显著差异。
  • 总体合并差异指数为0.97(95%CI 0.85-1.10;ICC 0.831,p<0.001),各亚组结果一致。
  • 作者认为局部研究者评估的无进展生存期作为主要终点可靠,并对所有随机临床试验实施盲法独立中心审查的实用价值提出质疑。

核心结论

  • 局部研究者与盲法独立中心审查评估的无进展生存期之间一致性良好,支持局部研究者评估的无进展生存期作为转移性乳腺癌随机临床试验主要终点的可靠性,并对所有随机临床试验实施盲法独立中心审查的实用价值提出质疑。

研究设计与样本

  • 系统检索PubMed、Embase、Cochrane数据库及ASCO、SABCS、ESMO会议论文集至2023年1月4日(PROSPERO注册号CRD42021229865)。
  • 纳入2000年至2022年发表的、包含一线或二线治疗的转移性乳腺癌患者、并报告局部研究者与盲法独立中心审查评估的无进展生存期的所有随机临床试验。
  • 共分析24项研究、13168例患者;其中19项(79%)为一线治疗,18项(75%)为III期试验,23项(96%)以无进展生存期为主要终点。
  • 计算每项试验盲法独立中心审查评估与研究者评估的风险比之间的差异指数,采用固定效应模型获得总体合并差异指数,并用组内相关系数衡量两种评估风险比之间的一致性。

主要发现

  • 总体合并差异指数为0.97(95%CI 0.85-1.10;ICC 0.831,p<0.001),提示局部研究者与盲法独立中心审查评估的无进展生存期无统计学显著差异。
  • 该结果在所有分析的亚组中一致。

临床怎么用

  • 作者认为局部研究者评估的无进展生存期作为转移性乳腺癌随机临床试验主要终点可靠,并对所有随机临床试验实施盲法独立中心审查的实用价值提出质疑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In randomized clinical trials (RCTs), blinded independent central review (BICR) is used to minimize heterogeneity and bias associated with radiological response evaluation by local investigators. However, BICR adds costs and complexity to the trial management. We assessed the discrepancy index between progression-free survival (PFS) assessment by local investigators and by BICR in RCTs conducted in patients with metastatic breast cancer (MBC). METHODS: A systematic search of PubMed, Embase, Cochrane databases and conference proceedings (ASCO, SABCS, ESMO) was performed up to January 4, 2023 (PROSPERO: CRD42021229865). All RCTs published from 2000 to 2022, including MBC patients treated in first- or second-line, and reporting PFS assessed by local investigators and BICR were included. A discrepancy index between BICR-assessed and investigator-assessed HR was calculated for each trial and an overall combined DI was obtained using a fixed-effects model. The agreement between hazard ratios (HR) of PFS assessed by local investigators and BICR was measured using intraclass correlation coefficient (ICC). RESULTS: We analyzed 24 studies including 13,168 patients. Among them, 19 (79%) were in first-line, 18 (75%) were phase III trials and 23 (96%) had PFS as primary endpoint. The overall combined discrepancy index was 0.97 (95%CI 0.85-1.10; ICC 0.831, p < 0.001) suggesting no statistically significant difference in PFS assessment between local investigators and BICR. This result was consistent across all analyzed subgroups. CONCLUSIONS: The good concordance between local investigator and BICR assessments supports the reliability of local investigator-assessed PFS as primary endpoint for RCTs in MBC and questions the practical utility of implementing BICR in all RCTs.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jacobs F, Molinelli C, Martins-Branco D, et al. Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis. Eur J Cancer. 2023. PMID: 38103328. doi:10.1016/j.ejca.2023.113478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。